Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Patrick F. Fogarty"'
Autor:
Priya Patel, Yong Chen, Arianna Burton, Jose Alvir, Darren Kailung Jeng, Anna Stachel, Jiayin Xue, Emily Cibelli, Patrick F. Fogarty
Publikováno v:
Blood. 140:13136-13137
Autor:
Bingshu E. Chen, Sarit Assouline, Matthew D. Seftel, Ralph M. Meyer, Marina Djurfeldt, Norbert Schmitz, Shen Li, Armand Keating, Michael Crump, Caterina Stelitano, Annette E. Hay, Sue Robinson, Tara Baetz, Eric Van Den Neste, Christian Gisselbrecht, Patrick F. Fogarty, Lois E. Shepherd
Publikováno v:
Blood Adv
The conditional survival of patients after frontline therapy for diffuse large B-cell lymphoma (DLBCL) approaches that of the general population once patients have survived disease free for 2 years. We sought to determine the conditional survival of
Autor:
Jonathan de Courcy, Emily Rubinstein, Dean Spurden, Jose Alvir, A Chhabra, Andreas M. Pleil, Bartholomew J Tortella, Simon Harris, Patrick F. Fogarty, Jennifer Mellor
Publikováno v:
Blood Coagul Fibrinolysis
Standard-of-care treatment for haemophilia A or B is to maintain adequate coagulation factor levels through clotting factor administration. The current study aimed to evaluate annualised bleeding rates (ABR) and treatment adherence for haemophilia A
Publikováno v:
Stem Cell Therapy for Autoimmune Disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77209d7ef85e7003997fccf513b8e839
https://doi.org/10.1201/9780367813895-47
https://doi.org/10.1201/9780367813895-47
Autor:
Margaret V. McDonald, Dean Spurden, Andreas M. Pleil, Patrick F. Fogarty, Bartholomew J Tortella, A Chhabra, Jose Alvir
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 24:643-653
Hemophilia B requires replacement therapy with factor IX (FIX) coagulation products to treat and prevent bleeding episodes. A recently introduced extended half-life (EHL) recombinant FIX replacement product provided the opportunity to compare the amo
Autor:
Patrick F. Fogarty, Youlia M. Kirova, Marie Bannier, Christophe Bonnet, Bohrane Slama, Hervé Tilly, Romain Bosc, Fabien Le Bras, Luc Mathieu Fornecker, Emmanuelle Nicolas-Virelizier, Lucie Oberic, Thua-Ha Dao, Corinne Haioun, Romain Ricci, Manon Croix, Luc Xerri, Emmanuel Bachy, Emmanuel Itti, Lionel Tortolano, Marc André, Camille Laurent, Jean Marc Schiano De Colella, Virginie Fataccioli, Alexandra Traverse-Glehen, Nadia Amara, Philippe Gaulard
Publikováno v:
Blood. 138:1387-1387
Background: Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare form of T-cell lymphoma arising adjacent to a breast implant, recently recognized as a provisional entity in the 2017 revised World Health Organization (WHO) lym
Publikováno v:
Haemophilia. 23:759-768
Introduction Factor VIII (FVIII) or factor IX (FIX)-deficient haemophilic patients display deficits in platelet and fibrin deposition under flow detectable in microfluidics. Compared to fibrin generation, decreased platelet deposition in haemophilic
Publikováno v:
Haemophilia. 23:400-407
INTRODUCTION von Willebrand disease (VWD) is one of the most common inherited bleeding disorders. AIM Investigate the impact of the VWD bleeding tendency on in-hospital management of acute coronary syndromes (ACS). METHODS Using discharge data from t
Autor:
Craig M. Kessler, Charity G. Moore, Kathleen E. Brummel-Ziedins, Patrick F. Fogarty, Leslie Raffini, Jonathan G. Yabes, A. T. Neff, Neil C. Josephson, Margaret V. Ragni
Publikováno v:
Haemophilia. 23:e43-e46
Autor:
Amit, Chhabra, Patrick F, Fogarty, Bartholomew J, Tortella, Dean, Spurden, José, Alvir, Margaret, McDonald, Jennifer, Hodge, Andreas M, Pleil
Publikováno v:
Managed care (Langhorne, Pa.). 27(10)
To identify international units (IUs) dispensed and consequent expenditures for standard half-life (SHL) versus extended half-life (EHL) recombinant factor VIII (rFVIII) replacement products in hemophilia A patients in a real-world setting.Two U.S. c